# Efficacy Study of ABR-215050 to Treat Prostate Cancer

> **NCT00560482** · PHASE2 · COMPLETED · sponsor: **Active Biotech AB** · enrollment: 206 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ABR-215050, tasquinimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00560482
- **Lead sponsor:** Active Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-06
- **Final completion:** 2015-08
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2015-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560482, "Efficacy Study of ABR-215050 to Treat Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00560482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*